Linda Garland, MD, is a thoracic medical oncologist and translational researcher with expertise in lung cancer and mesothelioma. She serves as director, Clinical Research in Thoracic Oncology, and director, Clinical Lung Cancer Program, at the University of Arizona Cancer Center, an NCI-designated Comprehensive Cancer Center.
Dr. Garland has designed investigator-initiated translational clinical trials with novel targeted agents in advanced lung cancer and mesothelioma. She participates in chemoprevention efforts at the UA Cancer Center through serving as co-investigator and medical director of the N01-supported UA Cancer Center’s Cancer Prevention and Control Program and the PI on sequential NCI-funded lung cancer prevention trials. She participates in translational collaboration with several basic scientists in preclinical development of novel cancer agents and imaging biomarkers.
Further, Dr. Garland collaborates with University of Arizona Biomedical Engineering in serving as a co-investigator for a randomized trial of a novel exercise intervention for cancer patients with peripheral neuropathy that provides evidence of improved balance outcomes relevant to fall prevention with the novel exercise intervention.
Dr. Garland previously served for 10 years on the University of Arizona Institutional Review Board (IRB).
Experimental therapeutics with a focus on malignant diseases of the chest Lung cancer Mesothelioma Rare mediastinal tumors